LunaPBC Clinches USD 4.6 Million To Accelerate Community-Owned Genomic And Health Data Platform Developments

Healthcare News

LunaPBC_Clinches-USD-4.6-Million-To-Accelerate-Community-Owned-Genomic-And-Health-Data-Platform-Developments LunaPBC Clinches USD 4.6 Million To Accelerate Community-Owned Genomic And Health Data Platform DevelopmentsLunaPBC, a San Diego CA-based first community-owned genomic and health data platform, has clinched USD 4.6 million in funding round. The company plans to use the funds to stimulate research partnerships, onboard new partners like Genetic Alliance, and expand platform development and marketing teams. The funding round was led by ARCH Venture Partners, Bain Capital Ventures, F-Prime Capital, Illumina Ventures, and Osage University Partners. With this round, the company’s total funding has reached to USD 7.6 million.

LunaPBC, which was founded back in 2017, is a health and genomic data platform owned by its community of personal health information donors. LunaDNA enables individuals to securely and privately share their medical data to speed up health research, advance quality of life, drive smarter healthcare, and share in the monetary value that flows from that platform. The platform will reward individuals for sharing health data and promises utility to pharmaceutical, insurance, and healthcare IT companies, as they advance health outcomes through the breakthroughs of new therapies and a deeper understanding of patient outcomes. In December last year, LunaDNA received a precedent-setting qualification from the U.S. Securities and Exchange Commission (SEC) to recognize an individual’s genomic and health data as currency with which to acquire shares of ownership in the Company. This offering makes sure members share in the value created from research performed on the platform.

Currently, the platform accepts DNA files from vendors including 23andMe, AncestryDNA, MyHeritage, and FamilyTree DNA, along with LunaDNA-generated health surveys. As per the reports, LunaPBC will contract with non-profits, pharmaceutical companies, academic institutions, and other research groups to empower access to the platform for medical research.